Q1 EPS Estimate for Soleno Therapeutics Lifted by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Stock analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Soleno Therapeutics in a report issued on Wednesday, March 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.93 for the quarter, up from their previous estimate of $0.88. HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q2 2026 earnings at $1.02 EPS and FY2027 earnings at $7.50 EPS.

SLNO has been the subject of a number of other reports. Robert W. Baird set a $107.00 price target on Soleno Therapeutics in a report on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Zacks Research downgraded shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. TD Cowen reduced their target price on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Finally, Wells Fargo & Company decreased their price target on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.85.

Soleno Therapeutics Trading Up 1.2%

Shares of Soleno Therapeutics stock opened at $38.57 on Thursday. Soleno Therapeutics has a 1 year low of $32.63 and a 1 year high of $90.32. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. The business has a 50 day moving average price of $41.77 and a 200 day moving average price of $52.42. The company has a market capitalization of $1.99 billion, a P/E ratio of 167.70 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million.

Institutional Investors Weigh In On Soleno Therapeutics

Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP increased its holdings in shares of Soleno Therapeutics by 272.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock worth $156,298,000 after buying an additional 1,691,057 shares during the last quarter. Braidwell LP acquired a new stake in Soleno Therapeutics during the third quarter worth about $86,662,000. Janus Henderson Group PLC lifted its stake in shares of Soleno Therapeutics by 18.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock valued at $332,302,000 after purchasing an additional 1,122,015 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Soleno Therapeutics by 132.3% during the 3rd quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock worth $101,435,000 after purchasing an additional 854,551 shares during the period. Finally, Commodore Capital LP increased its position in Soleno Therapeutics by 121.3% during the 3rd quarter. Commodore Capital LP now owns 1,350,000 shares of the company’s stock worth $91,260,000 after purchasing an additional 740,000 shares in the last quarter. 97.42% of the stock is owned by institutional investors and hedge funds.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.